Electrical Stimulation for Vision Neuroenhancement in Glaucoma

This study is testing a device called Eyetronic rtACS (repetitive, transorbital alternating current stimulation) to see if it can help improve vision in people with glaucoma. Glaucoma is an eye disease that can damage your optic nerve and lead to vision loss. The Eyetronic rtACS device uses a safe electrical current to try and improve how your eye and brain work together for vision. You might be able to join if you are at least 18 years old and have been diagnosed with primary open-angle glaucoma. The researchers will measure changes in your vision using tests like Visual Field Index (VFI), Mean Deviation (MD), and Pointwise Linear Regression (PLR) after 3 months to see if the treatment is effective. The current recruitment status is unclear.

Study design: This is an interventional study with 30 planned participants. Some participants will receive the active Eyetronic rtACS device, while others will receive a sham device that does not deliver stimulation.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed for at least 3 months to measure changes in their vision.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Electrical Stimulation for Vision Neuroenhancement in Glaucoma

Recruiting

NAAges 18+InterventionalTreatment

Stanford University

~30 participants

Updated 2025-11-04 on ClinicalTrials.gov

What's tested:Eyetronic rtACSSham rtACS

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Visual Field Index (VFI)

Measured over 3 Months

+2 more outcomes measured

Conditions

Glaucoma

Glaucoma Open-Angle

Where it's being run

1 sites across 1 states

California1

Study leadership

Jeffrey L Goldberg, MD PhD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Study Team

[email protected]

650-497-5942

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Participant must be at least 18.

Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).

Participant's clinical diagnosis must be consistent with primary open angle glaucoma (including but not limited to normal tension, low tension or general open angle) characterized by the following features: Mean deviation (MD) worse than -6 but better than -20 on reliable Humphrey Visual Field 24-2 testing

Participant's eye pressure must be clinically stable, with IOP \< 18.

If a participant has two eyes meeting study criteria, the worse eye as determined by visual field index (VFI) or patient preference, will be deemed includable. If both eyes qualify and have the same VFI, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study.

Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.

Exclusion

Participant is unable to comply with study procedures or follow-up visits.

Participant has a history of ocular herpes zoster.

Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study.

Participant has evidence of corneal opacification or lack of optical clarity.

Participant has uveitis or other ocular inflammatory disease.

Participant is receiving systemic steroids or other immunosuppressive medications.

Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration.

Participant is pregnant or lactating.

Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments.

Patients with opened skull, after trepanation or with heart and brain pacemaker.

Patients with implanted intracranial metals such as clippings, coilings, ventriculo-peritoneal shunts, endoprosthesis etc.

Patients with any skin damage in the area of electrode placement.

Children and comatose patients.

Patients with recent history of epileptic seizure.

Patients with uncontrolled high levels of blood pressure (\<160 mmHg) or uncontrolled high levels of intraocular pressure (\<27 mmHg).

Patients abusing drugs or alcohol.

What this trial measures

Visual Field Index (VFI)3 Months
Measuring the change in the Visual Field Index (VFI) from baseline to month 3.
Mean Deviation (MD)3 Months
Measuring the change in Mean Deviation on Visual Field from Baseline to Month 3.
Pointwise Linear Regression (PLR)3 Months
Measuring the PLR of the visual field points from baseline to Month 3.

Trialytics